Navigation Links
Ulcerative colitis treatment reduces need for surgery by almost half
Date:9/30/2009

ROCHESTER, Minn -- A new study led by Mayo Clinic researchers has found that ulcerative colitis patients had a 41 percent reduction in colectomy after a year when treated with infliximab, according to a study published in the October 2009 issue of Gastroenterology.

Ulcerative colitis, an inflammatory bowel disease (IBD) that causes chronic inflammation of the colon, is characterized by abdominal pain and diarrhea. Like Crohn's disease, another common IBD, ulcerative colitis can be debilitating and often lead to colectomy or surgical removal of the colon.

"Our purpose in this study was to see if the use of infliximab for ulcerative colitis would reduce the need for surgery," says William Sandborn, M.D., a Mayo Clinic gastroenterologist and lead author of the study. "We found that treatment with infliximab reduced the need for colectomy by 41 percent compared to patients treated with placebo."

In this multi-center, international study, 728 patients received placebo or infliximab (5 or 10 mg/kg) for 46 weeks and were monitored for hospitalization or surgical outcomes. Eighty-seven percent (630 of 728) had complete follow-up for the endpoint of whether or not they had colectomy, while the remaining 13 percent (98 of 728) of patients had follow-up for less then a year, with a median follow-up of 6.2 months in these patients. The research showed that treatment with infliximab at 0, 2 and 6 and then every 8 weeks reduced the incidence of colectomy through 54 weeks by 41 percent in outpatients with moderately-to-severe active ulcerative colitis.

The cumulative incidence of colectomy through 54 weeks was 10% for infliximab and 17% for placebo (p=0.02). Compared with placebo, fewer ulcerative colitis-related hospitalizations and surgeries/procedures occurred with infliximab therapy.

"One of the most feared outcomes for ulcerative colitis patients is surgical removal of the colon," says Dr. Sandborn. "Our research hopes to provide other treatment solutions for patients beyond surgery."

Previous research has shown that infliximab therapy induced clinical remission and bowel healing for colitis patients. This new research provides more information and options for patients struggling with this difficult disease, explains Dr. Sandborn.


'/>"/>

Contact: Amy Tieder
tieder.amy@mayo.edu
507-293-0969
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. New therapeutic targets in the treatment of ulcerative colitis
2. Narrow band imaging colonoscopy identifies flat dysplastic lesions in ulcerative colitis patients
3. Nationwide Survey Reveals Differing Physician and Patient Perceptions Regarding Impact of Ulcerative Colitis on Patients Lives
4. Although Remicade and Humira Are Being Increasingly Prescribed for Crohns Disease and Ulcerative Colitis, Insurers Are Subjecting Both Drugs to Multiple Cost-Control Strategies
5. Shire Launches Patient Education Forums on Better Managing the Challenges of Ulcerative Colitis
6. Medical Futures signs North American licensing rights to New Biologic agent for Ulcerative Colitis
7. Study underway to find an alternative cure for Crohns disease and ulcerative colitis
8. Long-Term Safety Data on Lialda(TM) (mesalamine) for Patients With Ulcerative Colitis Published in Leading GI Journal
9. Can rectal vitamin E induce remission in patients with mild to moderate ulcerative colitis?
10. Companies Pay a High Price for Employees With Crohns Disease and Ulcerative Colitis, According to Study From Thomson Reuters
11. Identification of genetic markers for ulcerative colitis could lead to treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... ... exclusively to funding innovative lymphoma research and serving the lymphoma community through a ... to the La Gorce Country Club in Miami Beach to host its Swirl: ...
(Date:2/23/2017)... ... February 23, 2017 , ... The American Cleft Palate-Craniofacial Association ... Annual Meeting. KLS is a longtime supporter of the event. , "We are ... Platinum Sponsor," said Dr. Bob Havlik, 2017 ACPA President. "KLS Martin has a long ...
(Date:2/23/2017)... ... ... Hamlin Dental Group and Dr. Hamid Reza, dentist in North Hollywood ... of February, patients who visit Hamlin Dental Group will receive a ticket for a ... the Cheesecake Factory. , Tickets are available for routine dental visits and other ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... approved content provider for the National Institute for Health and Care Excellence ... care-related organizations in the National Health Service (NHS) to search, order and purchase ...
(Date:2/23/2017)... ... February 23, 2017 , ... Dr. David Mahon leads ... NV 89052. Dr. Mahon was named a 2017 Top Patient Rated Henderson Dentist ... an online directory that recognizes local physicians and dentists who have earned high ratings ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... 23, 2017 Report analyzes the worldwide markets for ... analytics for the US, Canada , ... Asia-Pacific , Latin America , ... for the period 2015 through 2022. Also, a six-year historic ... are derived from primary and secondary research. Company profiles are ...
(Date:2/24/2017)... Australia , Feb. 23, 2017  Directors from Pharma To ... two companies have joined forces, resulting in the founding of Pharma ... Pharma To Market are pleased to announce their expansion ... office in Singapore . The company are delighted ... as Co-Director of the Singapore based entity. ...
(Date:2/24/2017)... YORK , Feb. 23, 2017  The ... 330.6 million by 2021 from USD 275.9 million ... Read the full report: http://www.reportlinker.com/p04718602-summary/view-report.html ... increasing spending on pharmaceutical R&D, and growth in ... driving the market growth for particle counters. On ...
Breaking Medicine Technology: